General Cell Collection Detail
orders accepted or email / fax
your order to us.
General Cell Collection: NCI-H69/LX4
|Cell Line Name:||NCI-H69/LX4|
|Keywords:||Human Caucasian small cell lung carcinoma, drug-resistant|
|Cell Line Description:||NCI-H69/LX4 has been established by exposure of the parent line, H69 (ECACC catalogue no. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.|
|Growth Mode:||Aggregates in suspension|
|Subculture Routine:||Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO2; 37°C|
|Culture Medium:||RPMI + 2mM Glutamine + 0.4µg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr P Twentyman / Dr K Wright, MRC Clinical Oncology Unit, Cambridge, UK|
|References:||Br J Cancer 1992;65:335; Br J Cancer 1986;53:529|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Research Council Deposit:||Yes|
The HPA Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by HPA Culture Collections are accurate, HPA Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and HPA Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by HPA Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.